Aeterna Zentaris to Present at the Virtual Investor 2022 Top Picks Conference
January 20 2022 - 8:05AM
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the
“Company”), a specialty biopharmaceutical company developing and
commercializing a diversified portfolio of pharmaceutical and
diagnostic products, today announced that Dr. Klaus Paulini, Chief
Executive Officer of Aeterna Zentaris, will present at the
Virtual Investor 2022 Top Picks Conference on Wednesday, January
26, 2022 at 9:00 AM ET.
As part of the virtual event, the Company will
provide a brief presentation, followed by a moderated discussion
and an interactive Q&A session. In addition to the moderated
portion of the event, all investors and interested parties will
have the opportunity to submit questions live during the event.
Interested parties may also pre-submit questions in advance of the
live event, which can be sent via the conference website at
virtualinvestorco.com. The Company will answer as many questions as
possible during the event.
A live video webcast of the presentation
will be available on the Events page in the Investors section of
the Company’s website (www.zentaris.com). A webcast replay will be
available two hours following the live presentation and will be
accessible for one year.
About Aeterna Zentaris Inc.
Aeterna Zentaris is a specialty
biopharmaceutical company developing and commercializing a
diversified portfolio of pharmaceutical and diagnostic products
focused on areas of significant unmet medical need. The Company's
lead product, macimorelin (Macrilen™), is the first and only U.S.
FDA and European Commission approved oral test indicated for the
diagnosis of adult growth hormone deficiency (AGHD). The Company is
leveraging the clinical success and compelling safety profile of
macimorelin to develop it for the diagnosis of childhood-onset
growth hormone deficiency (CGHD), an area of significant unmet
need, in collaboration with Novo Nordisk.
Aeterna Zentaris is dedicated to the development
of therapeutic assets and has recently taken steps to establish a
growing pre-clinical pipeline to potentially address unmet medical
needs across a number of indications, including neuromyelitis
optica spectrum disorder (NMOSD), Parkinson’s disease (PD),
hypoparathyroidism and amyotrophic lateral sclerosis (ALS; Lou
Gehrig's disease). Additionally, the Company is developing an oral
prophylactic bacterial vaccine against SARS-CoV-2 (COVID-19) and
chlamydia.
For more information, please visit
www.zentaris.com and connect with the Company on Twitter, LinkedIn
and Facebook.
Investor Contact:
Jenene ThomasJTC TeamT (US): +1 (833) 475-8247E:
aezs@jtcir.com
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Sep 2023 to Sep 2024